CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

Core Viewpoint - CytoMed Therapeutics Limited addresses and rejects recent misleading claims regarding its research programs, clinical progress, and operations, emphasizing its commitment to transparency and accurate communication [1][2][5]. Company Overview - CytoMed is a clinical stage biopharmaceutical company based in Singapore, focused on developing affordable donor-derived cell-based immunotherapies for various cancers, including blood and solid tumors [1][7]. - The company was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [7]. Research and Development - The company's research primarily focuses on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, grounded in established immunological science [3]. - CytoMed's lead CAR γδ T cell program has received regulatory approval for a first-in-human clinical trial, which is currently ongoing at the National University Hospital in Singapore [3]. - Other therapeutic candidates, including iPSC-derived γδ NKT cell candidates, are still in preclinical development [4]. Regulatory and Operational Compliance - CytoMed asserts that it operates in compliance with applicable regulations and follows appropriate development practices for its current stage [5]. - The company emphasizes that any claims regarding its regulatory status, manufacturing capabilities, governance, or financial transparency that contradict its statements are inaccurate or taken out of context [5]. Commitment to Transparency - CytoMed is dedicated to advancing its pipeline responsibly and ensuring timely communication of accurate information through official disclosures [6]. - The company reserves the right to take action against the dissemination of false or misleading information that could harm its reputation or stakeholders [6].